TransMedics Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
February 26, 2024 at 04:20 pm EST
Share
TransMedics Group, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 81.17 million compared to USD 31.38 million a year ago. Net income was USD 4.03 million compared to net loss of USD 6.72 million a year ago.
Basic earnings per share from continuing operations was USD 0.12 compared to basic loss per share from continuing operations of USD 0.21 a year ago. Diluted earnings per share from continuing operations was USD 0.12 compared to diluted loss per share from continuing operations of USD 0.21 a year ago.
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.